158 related articles for article (PubMed ID: 37278160)
1. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor.
Alberti M; Sainas S; Ronchi E; Lolli ML; Boschi D; Rizzi M; Ferraris DM; Miggiano R
FEBS Lett; 2023 Aug; 597(16):2119-2132. PubMed ID: 37278160
[TBL] [Abstract][Full Text] [Related]
2. Kinetic and structural studies of Mycobacterium tuberculosis dihydroorotate dehydrogenase reveal new insights into class 2 DHODH inhibition.
Teixeira O; Martins IBS; Froes TQ; de Araujo AS; Nonato MC
Biochim Biophys Acta Gen Subj; 2023 Jul; 1867(7):130378. PubMed ID: 37150227
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods.
Higgins WT; Vibhute S; Bennett C; Lindert S
J Chem Inf Model; 2024 Jan; 64(2):435-448. PubMed ID: 38175956
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
5. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
[TBL] [Abstract][Full Text] [Related]
6. Recent advances on patents of
Gehlot P; Vyas VK
Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
[TBL] [Abstract][Full Text] [Related]
7. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
8. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Singh A; Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
[TBL] [Abstract][Full Text] [Related]
9. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
[TBL] [Abstract][Full Text] [Related]
10. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
11. Structural and Functional Analyses of Inhibition of Human Dihydroorotate Dehydrogenase by Antiviral Furocoumavirin.
Nakahara M; Watanabe S; Sato M; Okumura H; Kawatani M; Osada H; Hara K; Hashimoto H; Watanabe K
Biochemistry; 2024 May; 63(10):1241-1245. PubMed ID: 38724483
[TBL] [Abstract][Full Text] [Related]
12. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain.
Pinheiro MP; Iulek J; Cristina Nonato M
Biochem Biophys Res Commun; 2008 May; 369(3):812-7. PubMed ID: 18302934
[TBL] [Abstract][Full Text] [Related]
14. The dihydroorotate dehydrogenases: Past and present.
Reis RAG; Calil FA; Feliciano PR; Pinheiro MP; Nonato MC
Arch Biochem Biophys; 2017 Oct; 632():175-191. PubMed ID: 28666740
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the function and inhibition of dihydroorotate dehydrogenase from Schistosoma mansoni.
de Mori RM; Aleixo MAA; Zapata LCC; Calil FA; Emery FS; Nonato MC
FEBS J; 2021 Feb; 288(3):930-944. PubMed ID: 32428996
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
[TBL] [Abstract][Full Text] [Related]
18. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
19. A Novel mechanism of herbicide action through disruption of pyrimidine biosynthesis.
Kang IH; Emptage RP; Kim SI; Gutteridge S
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2313197120. PubMed ID: 37988466
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
